Allena Pharmaceuticals, Inc. Property, Plant, Equpment (Net)

Property, Plant, Equpment (Net) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Property, Plant, Equpment (Net) growth rates and interactive chart. Property, plant, and equipment (aslo called PP&E) are a company's physical or tangible long-term assets that typically have a life of more than one year. Examples of PP&E include buildings, machinery, land, office equipment, furniture, and vehicles.


Highlights and Quick Summary

  • Property, Plant, Equpment (Net) for the quarter ending March 31, 2022 was $1.05 Million (a -35.63% decrease compared to previous quarter)
  • Year-over-year quarterly Property, Plant, Equpment (Net) decreased by -41.49%
  • Annual Property, Plant, Equpment (Net) for 2021 was $1.63 Million (a 4.43% increase from previous year)
  • Annual Property, Plant, Equpment (Net) for 2020 was $1.56 Million (a 64.11% increase from previous year)
  • Annual Property, Plant, Equpment (Net) for 2019 was $950 Thousand (a 84.82% increase from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Property, Plant, Equpment (Net) of Allena Pharmaceuticals, Inc.

Most recent Property, Plant, Equpment (Net)of ALNA including historical data for past 10 years.

Interactive Chart of Property, Plant, Equpment (Net) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Property, Plant, Equpment (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $1.05
2021 $1.63 $1.79 $1.79 $1.84 $1.63
2020 $1.56 $0.31 $0.32 $0.36 $1.56
2019 $0.4 $0.44 $0.47 $0.49 $0.95
2018 $0.51 $0.47 $0.2 $0.13 $0.51
2017 $0.13 $0.13 $0.13
2016 $0.17
2015 $0.27 $0.09

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.